Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:05am, Friday, 27'th Sep 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
08:30am, Thursday, 26'th Sep 2024
Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time.
AbbVie's Parkinson's Disease drug meets main goal in late-stage trial
08:08am, Thursday, 26'th Sep 2024
AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
08:00am, Thursday, 26'th Sep 2024
Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III c
Bristol Myers Squibb Vs. AbbVie Stock
07:00am, Thursday, 26'th Sep 2024
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenue
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
06:50pm, Wednesday, 25'th Sep 2024
The latest trading day saw AbbVie (ABBV) settling at $191.26, representing a -1.16% change from its previous close.
My Dividend Stock Portfolio: New August Dividend Record - 101 Holdings With 17 Buys
08:10am, Wednesday, 25'th Sep 2024
Investment activity remained high in August, focusing on BDCs aiming to increase dividend income by at least $100 each month. Main portfolio picks included Ares Capital, Hercules Capital and Goldman S
New post-hoc analysis demonstrate d efficacy of RINVOQ® (upadacitinib) in moderate-to-severe atopic dermatitis patients with varying degrees of severity in head and neck involvement, with results i
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
11:01am, Monday, 23'rd Sep 2024
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
Raise Cash And Sell Trash
08:05am, Saturday, 21'st Sep 2024
As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede recessio
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
07:32am, Friday, 20'th Sep 2024
NORTH CHICAGO, Ill. , Sept. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
04:21am, Thursday, 19'th Sep 2024
AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former lea
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
06:51pm, Tuesday, 17'th Sep 2024
AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 17'th Sep 2024
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two stocks is more attractive to value investors?
Final Trades: TransDigm, BJ's Wholesale, AbbVie and the SMH
01:26pm, Monday, 16'th Sep 2024
The Investment Committee give you their top stocks to watch for the second half.
